Literature DB >> 22296092

Ultraviolet A and photosensitivity during vemurafenib therapy.

Reinhard Dummer, Jeannine Rinderknecht, Simone M Goldinger.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22296092     DOI： 10.1056/NEJMc1113752

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  35 in total

Review 1.  Cutaneous toxicities of new treatments for melanoma.

Authors:  A Boada; C Carrera; S Segura; H Collgros; P Pasquali; D Bodet; S Puig; J Malvehy
Journal:  Clin Transl Oncol       Date:  2018-05-24       Impact factor: 3.405

Review 2.  [UV phototherapy : UV phototherapy and photodiagnostics-a practical overview].

Authors:  H Stege; K Ghoreschi; C Hünefeld
Journal:  Hautarzt       Date:  2021-01-04       Impact factor: 0.751

Review 3.  Managing the skin toxicities from new melanoma drugs.

Authors:  John C Mavropoulos; Timothy S Wang
Journal:  Curr Treat Options Oncol       Date:  2014-06

4.  Diverse cutaneous side effects associated with BRAF inhibitor therapy: a clinicopathologic study.

Authors:  Emily Y Chu; Karolyn A Wanat; Christopher J Miller; Ravi K Amaravadi; Leslie A Fecher; Marcia S Brose; Suzanne McGettigan; Lydia R Giles; Lynn M Schuchter; John T Seykora; Misha Rosenbach
Journal:  J Am Acad Dermatol       Date:  2012-05-18       Impact factor: 11.527

Review 5.  [Cutaneous side effects of targeted cancer drugs].

Authors:  J Below; B Homey; P A Gerber
Journal:  Hautarzt       Date:  2017-01       Impact factor: 0.751

6.  Protein oxidation and DNA repair inhibition by 6-thioguanine and UVA radiation.

Authors:  Quentin Gueranger; Feng Li; Matthew Peacock; Annabel Larnicol-Fery; Reto Brem; Peter Macpherson; Jean-Marc Egly; Peter Karran
Journal:  J Invest Dermatol       Date:  2013-11-27       Impact factor: 8.551

7.  Analysis of dermatologic events in vemurafenib-treated patients with melanoma.

Authors:  Mario E Lacouture; Madeleine Duvic; Axel Hauschild; Victor G Prieto; Caroline Robert; Dirk Schadendorf; Caroline C Kim; Christopher J McCormack; Patricia L Myskowski; Olivia Spleiss; Kerstin Trunzer; Fei Su; Betty Nelson; Keith B Nolop; Joseph F Grippo; Richard J Lee; Matthew J Klimek; James L Troy; Andrew K Joe
Journal:  Oncologist       Date:  2013-03-01

8.  Appearance of New Vemurafenib-associated Melanocytic Nevi on Normal-appearing Skin: Case Series and a Review of Changing or New Pigmented Lesions in Patients with Metastatic Malignant Melanoma After Initiating Treatment with Vemurafenib.

Authors:  Philip R Cohen; Agop Y Bedikian; Kevin B Kim
Journal:  J Clin Aesthet Dermatol       Date:  2013-05

Review 9.  Avoiding Severe Toxicity From Combined BRAF Inhibitor and Radiation Treatment: Consensus Guidelines from the Eastern Cooperative Oncology Group (ECOG).

Authors:  Christopher J Anker; Kenneth F Grossmann; Michael B Atkins; Gita Suneja; Ahmad A Tarhini; John M Kirkwood
Journal:  Int J Radiat Oncol Biol Phys       Date:  2016-06-01       Impact factor: 7.038

10.  Unusual acute and delayed skin reactions during and after whole-brain radiotherapy in combination with the BRAF inhibitor vemurafenib. Two case reports.

Authors:  B Schulze; M Meissner; M Wolter; C Rödel; C Weiss
Journal:  Strahlenther Onkol       Date:  2013-12-22       Impact factor: 3.621
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.